Elicio Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Elicio Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q2 2024.
  • Elicio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $350K, a 25.4% increase year-over-year.
  • Elicio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $1.35M, a 43.9% increase year-over-year.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.18M, a 104% increase from 2022.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $579K, a 95.2% decline from 2021.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12M, a 155% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.35M $350K +$71K +25.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $1.28M $324K +$100K +44.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.18M $337K +$12K +3.69% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $1.17M $339K +$229K +208% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $938K $279K +$166K +147% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $772K $224K +$193K +623% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $579K $325K -$1.7M -83.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $2.28M $110K -$2.07M -95% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $4.35M $113K -$2.61M -95.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $6.96M $31K -$5.09M -99.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $12M $2.02M +$860K +74% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 $11.2M $2.18M +$557K +34.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.6M $2.72M +$1.62M +148% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $9M $5.12M +$4.29M +515% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $4.72M $1.16M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $1.63M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $1.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $832K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.